These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9158644)

  • 1. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.
    Morocutti C; Amabile G; Fattapposta F; Nicolosi A; Matteoli S; Trappolini M; Cataldo G; Milanesi G; Lavezzari M; Pamparana F; Coccheri S
    Stroke; 1997 May; 28(5):1015-21. PubMed ID: 9158644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indobufen: an updated review of its use in the management of atherothrombosis.
    Bhana N; McClellan KJ
    Drugs Aging; 2001; 18(5):369-88. PubMed ID: 11392445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack.
    Saxena R; Koudstaal P
    Cochrane Database Syst Rev; 2004 Oct; (4):CD000187. PubMed ID: 15494992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Italian Study on Atrial Fibrillation (SIFA): status report].
    Amabile G; Matteoli S; Fattapposta F; Lavezzari M; Trappolini M; Heiman F; Morocutti C
    Cardiologia; 1993 Dec; 38(12 Suppl 1):327-32. PubMed ID: 8020032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
    G Chir; 1995 Mar; 16(3):137-9. PubMed ID: 7547128
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.
    Taylor FC; Cohen H; Ebrahim S
    BMJ; 2001 Feb; 322(7282):321-6. PubMed ID: 11159653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.
    Fornaro G; Rossi P; Mantica PG; Caccia ME; Aralda D; Lavezzari M; Pamparana F; Milanesi G
    Circulation; 1993 Jan; 87(1):162-4. PubMed ID: 8419003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thromboembolism in non-rheumatic atrial fibrillation].
    Pengo V
    Haematologica; 2001 Sep; 86(9 Suppl):5-11. PubMed ID: 11759619
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation.
    Pengo V; Zasso A; Barbero F; Banzato A; Nante G; Parissenti L; John N; Noventa F; Dalla Volta S
    Am J Cardiol; 1998 Aug; 82(4):433-7. PubMed ID: 9723629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group.
    Yamaguchi T
    Stroke; 2000 Apr; 31(4):817-21. PubMed ID: 10753981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation.
    Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
    Int J Clin Pharm; 2015 Feb; 37(1):53-9. PubMed ID: 25428444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial.
    Gao XY; Liu YM; Zheng DN; Li YW; Li H; Xiong XL; Chen HY; Wang H; Yu XY; Qu K; Jin J; Lin B; He Q
    Ren Fail; 2023 Dec; 45(1):2163505. PubMed ID: 36636998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.